Duloxetine for the treatment of fibromyalgia

Expert Review of Clinical Immunology

Volumn 6, Issue 5, 2010, Pages 745-756

  Wright, Cheryl L ^a   Mist, Scott D ^a   Ross, Rebecca L ^a   Jones, Kim D ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

duloxetine; fibromyalgia; pain; serotonin and norepinephrine inhibitors; SNRI

Indexed keywords

ACETYLSALICYLIC ACID; DULOXETINE; FLUPIRTINE; HARKOSERIDE; IBUPROFEN; MILNACIPRAN; NALTREXONE; OXYBATE SODIUM; PREGABALIN; WARFARIN;

ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERHIDROSIS; HYPERSOMNIA; HYPERTENSION; HYPOMANIA; INSOMNIA; MANIA; NAUSEA; NONHUMAN; PHARMACODYNAMICS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SYMPTOM; UPPER ABDOMINAL PAIN; UPPER GASTROINTESTINAL BLEEDING; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; FIBROMYALGIA; HUMANS; PAIN; PAIN MEASUREMENT; THIOPHENES;

EID: 77956522867     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.64     Document Type: Review

References (97)

1. Bennett RM. Clinical manifestations and diagnosis of fbromyalgia. Rheumatol. Dis. Clin. North Am. 35, 215-232 (2009).
2. Wolfe F, Clauw DJ, Fitzcharles M-A et al. The American College of Rheumatology preliminary diagnostic criteria for fbromyalgia and measurement of symptom severity. Arthritis Care Res. 62, 600-610 (2010).
3. Lawrence RC, Felson DT, Helmick CG et al. Estimates of arthritis and other rheumatic conditions in the United States, Part II. Arthritis Rheum. 58, 26-35 (2008).
4. Annemans L, Le Lay K, Taieb C. Societal and patient burden of fbromyalgia syndrome. Pharmacoeconomics 27, 547-559 (2009).
5. Silverman S, Dukes EM, Johnston SS et al. The economic burden of fbromyalgia: comparative analysis with rheumatoid arthritis. Curr. Med. Res. Opin 25, 829-840 (2009).
6. White LA, Birnbaum HG, Kaltenboeck A et al. Employees with fbromyalgia: medical comorbidity, healthcare costs, and work loss. J. Occup. Environ. Med. 50, 13-24 (2008).
7. Wolfe F, Anderson J, Harkness D et al. Work and disability status of persons with fbromyalgia. J. Rheumatol. 24, 1171-1178 (1997).
8. Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 Criteria for the Classifcation of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 33, 160-172 (1990).
9. Geisser ME, Gracely RH, Giesecke T et al. The association between experimental and clinical pain measures among persons with fbromyalgia and chronic fatigue syndrome. Eur. J. Pain 11, 202-207 (2006).
10. Staud R, Nagel S, Robinson ME et al Enhanced central pain processing of fbromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain 145, 96-104 (2009).
11. Ge H-Y, Nie H, Madeleine P et al Contribution of the local and referred pain from active myofascial trigger points in fbromyalgia syndrome. Pain 147, 233-240 (2009).
12. Staud R. Biology and therapy of fbromyalgia: pain in fbromyalgia syndrome. Arthritis Res. Ther. 8(2), 1-7 (2006).
13. Vierck JCJ. Mechanisms underlying development of spatially distributed chronic pain (fbromyalgia). Pain 124, 242-263 (2006).
14. Williams DA, Gracely RH. Biology and therapy of fbromyalgia. Functional magnetic resonance imaging fndings in fbromyalgia. Arthritis Res. Ther. 8(6), 1-8 (2006).
15. Gracely RH, Geisser ME, Giesecke T et al. Pain catastrophizing and neural responses to pain among persons with fbromyalgia. Brain 127, 835-843 (2004).
16. Gracely RH, Petzke F, Wolf JM et al. Functional magnetic resonance imaging evidence of augmented pain processing in fbromyalgia. Arthritis Rheum. 46, 1333-1343 (2002).
17. Harris RE, Sundgren, PC, Pang Y-X et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fbromyalgia. Arthritis Rheum. 58, 903-907 (2008).
18. Petrou M, Harris RE, Foerster BR et al. Proton MR spectroscopy in the evaluation of cerebral metabolism in patients with fbromyalgia: comparison with healthy controls and correlation with symptom severity. Am. J. Neuroradiol. 29, 913-918 (2008).
19. Landis CA, Lentz MJ, Rothermel J et al. Decreased sleep spindles and spindle activity in midlife women with fbromyalgia and pain. Sleep 2 7, 741-750 (2004).
20. Landis CA, Lentz MJ, Tsuji J et al. Pain, psychological variables, sleep quality, and natural killer cell activity in midlife women with and without fbromyalgia. Brain Behav. Immun. 18, 304-313 (2004).
21. Jones KD, Deodhar P, Lorentzen A, Bennett RM, Deodhar AA. Growth hormone perturbations in fbromyalgia: a review. Semin. Arthritis Rheum. 36, 357-379 (2007).
22. McLean SA, Williams DA, Stein PK et al. Cerebrospinal fuid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fbromyalgia. Neuropsychopharmacology 31, 2776-2782 (2006).
23. Wood PB, Glabus MF, Simpson R et al. Changes in gray matter density in fbromyalgia: correlation with dopamine metabolism. J. Pain 10, 609-618 (2009).
24. Wood PB, Ledbetter CR, Glabus MF et al. Hippocampal metabolite abnormalities in fbromyalgia: correlation with clinical features. J. Pain 10, 47-52 (2009).
25. Kuchinad A, Schweinhardt P, Seminowicz DA et al. Accelerated brain gray matter loss in fbromyalgia patients: premature aging of the brain? J. Neurosci. 27, 4004-4007 (2007).
26. Cohen H, Neumann L, Glazer Y et al. The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fbromyalgia. Clin. Exp. Rheumatol. 27, S51-S56 (2009).
27. Mease PJ, Choy EH. Pharmacotherapy of fbromyalgia. Rheumatol. Dis. Clin. North Am. 35, 359-372 (2009).
28. Carville SF, Arendt-Niels en S, Bliddal H et al. EULAR evidence-based recommendations for the management of fbromyalgia syndrome. Ann. Rheum. Dis. 67, 536-541 (2008).
29. Sarac AJ, Gur A. Complementary and alternative medical therapies in fbromyalgia. Curr. Pharm. Des. 12, 47-57 (2006).
30. Hassett AL, Gevirtz RN. Treatment for fbromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheumatol. Dis. Clin. North Am. 35, 393-407 (2009).
31. McVeigh JG, McGaughey H, Hall M et al The effectiveness of hydrotherapy in the management of fbromyalgia syndrome: a systematic review. Rheumatology Int. 29, 119-130 (2008).
32. Jones KD, Liptan GL. Exercise interventions in fbromyalgia: clinical applications from the evidence. Rheumatol. Dis. Clin. North Am. 35, 373-391 (2009).
33. Ang D, Chakr R, Mazzuca S, France CR, Steiner, J, Stump T Cognitive-behavioral therapy attenuates nociceptive responding in patients with fbromyalgia: a pilot study. Arthritis Care Res. 62, 618-623 (2010).
34. Valencia M, Alonso B, Alvarez MJ et al Effects of 2 physiotherapy programs on pain perception, muscular fexibility, and illness impact in women with fbromyalgia: a pilot study. J. Manipulative Physiol. Ther. 32, 84-92 (2009).
35. Targino RA, Imamura M, Kaziyama HHS et al. A randomized controlled trial of acupuncture added to usual treatment for fbromyalgia. J. Rehab. Med. 40, 582-588 (2008).
36. Mayhew E, Ernst E. Acupuncture for fbromyalgia-a systematic review of randomized clinical trials. Rheumatology 46, 801-804 (2007).
37. Babu AS, Mathew E, Danda D et al Management of patients with fbromyalgia using biofeedback: a randomized control trial. Indian J. Med. Sci. 61, 455-461 (2007).
38. Hassett AL, Radvanski DC, Vaschillo EG et al. A pilot study of the effcacy of heart rate variability (HRV) biofeedback in patients with fbromyalgia. Appl. Psychophysiol. Biofeed. 32, 1-10 (2007).
39. Boggio P, Amancia EJ, Correa CF et al. Transcranial DC stimulation coupled with TENS for the treatment of chronic pain: a preliminary study. Clin. J. Pain 25, 691-695 (2009).
40. Fregni F, Gimenes R, Valle AC et al. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fbromyalgia. Arthritis Rheum. 54, 3988-3998 (2006).
41. Carette S, Bell MJ, Reynolds WJ et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fbromyalgia: a randomized, double-blind clinical trial. Arthritis Rheum. 37, 32-40 (1994).
42. Mease PJ, Russell IJ, Arnold LM et al. A randomized, double-blind, placebo-controlled, Phase III trial of pregabalin in the treatment of patients with fbromyalgia. J. Rheumatol. 35, 502-514 (2008).
43. Branco JC, Zachrisson O, Perrot S et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fbromyalgia. J. Rheumatol. 37, 851-859 (2010).
44. Yalcin I, Tessier LH, Petit-Demoulière N et al. b2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. Neurobiol. Dis. 33(3), 386-394 (2009).
45. Munro G. Dopamine d(1) and d920 receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test. Eur. J. Pharmacol. 575, 66-74 (2007).
46. Melzack R. From the gate to the neuromatrix. Pain. 6(Suppl.), S121-S126 (1999).
47. Bonifazi M, Suman AL, Cambiaggi C et al. Changes in salivary cortisol and corticosteroid receptor-a mRNA expression following a 3-week multidisciplinary treatment program in patients with fbromyalgia. Psychoneuroendocrinology 31, 1076-1086 (2006).
48. McLean SA, Williams DA, Stein PK et al. Cerebrospinal fuid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fbromyalgia. Neuropsychopharmacology 31, 2776-2782 (2006).
49. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. Pain 79(1), 75-82 (1999).
50. Rainville P, Bao Q, V, Chrétien P. Pain-related emotions modulate experimental pain perception and autonomic responses. Pain 118(3), 306-318 (2005).
51. Arnold LM, Rosen A, Pritchett YL et al A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fbromyalgia with or without major depressive disorder. Pain 119, 5-15 (2005).
52. Perahia DGS, Pritchett YL, Desaiah D, Raskin J. Effcacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int. Clin. Psychopharmacol. 21, 311-317 (2006).
53. Pedersen L, Nielsen A, Blackburn-Munro G. Antinociception is selectively enhanced by parallel inhibition of multiple subtypes of monamine transporters in rat models of persistent and neuropathic pain. Psych oph arm aco logy 182, 551-561 (2005).
54. Clauw DJ. Fibromyalgia: update on mechanisms and management. J. Clin. Rheumatol. 13(2), 102-109 (2007).
55. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J. Pain 7(1), 43-48 (2006).
56. Harris RE, Clauw DJ, Scott DJ et al Decreased central mu-opioid receptor availability in fbromyalgia. J. Neurosci. 27(37), 10000-10006 (2007).
57. Ahmedzai SH, Boland J. Opioids for chronic pain: molecular and genomic basis of actions and adverse effects. Curr. Opin Support. Palliat. Care 1(2), 117-125 (2007).
58. Zucker DR, Ruthazer R, Schmid CH et al. Lessons learned combining N-of-1 trials to assess fbromyalgia therapies. J. Rheumatol. 33(10), 2069-2077 (2006).
59. Russell IJ, Perkins AT, Michalek JE. Sodium oxybate relieves pain and improves function in fbromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 60(1), 299-309 (2009).
60. Stoll AL. Fibromyalgia symptoms relieved by fupirtine: an open-label case series. Psychosomatics 41(4), 371-372 (2000).
61. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin. Pharmacother. 10(9), 1495-1500 (2009).
62. Wymer JP, Simpson J, Sen D, Bongardt S. Effcacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fxed-dose regimens. Clin. J. Pain 25(5), 376-385 (2009).
63. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 10(4), 663 (2009).
64. Younger J, Zautra AJ, Cummins ET. Effects of naltrexone on pain sensitivity and mood in fbromyalgia: no evidence for endogenous opioid pathophysiology. PLoS Med. 4(4), e5180 (2009).
65. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol. 40, 161-167 (2000).
66. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int. Clin. Psychopharmacol. 23, 161-169 (2008).
67. Skinner MH, Kuan H-Y, Pan A et al. Duloxetine is both an inhibitor and substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther. 73(3), 170-177 (2003).
68. Spina E, Santoro V, D'Arrigo C. Clinically relevent pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin. Ther. 30(7), 1206-1227 (2008).
69. Lobo ED, Quinlin T, O'Brien L, Knadler MP, Heathman M. Population pharmacokinetics of orally administered duloxetine in patients. Clin. Pharmacokinet. 48(3), 189-197 (2009).
70. Choy EHS, Mease PJ, Kajdasz DK et al. Safety and tolerability of duloxetine in the treatment of patients with fbromyalgia: pooled analysis of data from fve clinical trials. Clin. Rheumatol. 28, 1035-1044 (2009).
71. Lobo ED, Loghin C, Knadler MP et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin. Pharmacokinetics 47(2), 103-109 (2008).
72. Chan C, Yeo KP, Pan AX, Lim M, Knadler MP, Small DS. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br. J. Clin. Pharmacol. 63(3), 310-314 (2006).
73. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr. Med. Res. Opin. 23(1), 175-184 (2007).
74. Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner H-Y, Knadler MP. Metabolism, excretion and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos. 31(9), 1142-1150 (2003).
75. Arnold LM, Lu Y, Crofford LJ et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fbromyalgia patients with or without major depressive disorder. Arthritis Rheum. 50, 2974-2984 (2004).
76. Russell IJ, Mease PJ, Smith TR et al. Effcacy and safety of duloxetine for treatment of fbromyalgia in patients with or without major depressive disorder: results from a 6-month randomized, double-blind, placebo-controlled, fxed-dose trial. Pain 136, 432-444 (2008).
77. Chappell AS, Bradley L, Wiltse C et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fbromyalgia. Int. J. Gen. Med. 1, 91-102 (2008).
78. Chappell AS, Littlejohn G, Kajdasz DK et al. 1-year safety and effcacy study of duloxetine in patients with fbromyalgia. Clin. J. Pain 25(5), 365-375 (2009).
79. Farrar JT, Young JP Jr, LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94, 149-158 (2001).
80. Argoff CE, Misha-Miroslav B, Belgrade MJ et al. Consensus guidelines: treatment planning and options. Mayo Clin. Proc. 81(4), S12-S25 (2006).
81. Arnold LM, Pritchett YL, D'Souza DN et al. Duloxetine for the treatment of fbromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J. Womens Health 16(8), 1145-1156 (2007).
82. Arnold LM, Hudson JI, Wang F. Comparisons of the effcacy and safety of duloxetine for the treatment of fbromyalgia in patients with versus without major depressive disorder. Clin. J. Pain 25, 461-468 (2009).
83. Bradley LA, Wohlreich MM, Wang F et al. Pain response profle of patients with fbromyalgia treated with duloxetine. Clin. J. Pain 26, 498-504 (2010).
84. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain (review). Cochrane Database Syst. Rev. 4, CD007115 (2010).
85. Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 15(85) 168-172 (2006).
86. No authors listed. Duloxetine (cymbalta) for fbromyalgia. Med. Lett. Drugs Ther. 50(1291), 57-58 (2008).
87. Spielmans GI. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychother. Psychosomat. 77(1), 12-16 (2008).
88. Sclar D, Robison LM, Skaer TL. Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome. Headache 48(1), 126-129 (2008).
89. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profle of duloxetine. Drug Safe. 30(5), 437-455 (2007).
90. McCloskey D, Postoloche TT, Vittone BJ et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Trans. Res. J. Lab Clin. Med. 151(3), 168-172 (2008).
91. Loke Y, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-infammatory drugs. Aliment. Pharmacol. Ther. 27(1), 31-40 (2008).
92. Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch. Int. Med. 168(2), 180-185 (2008).
93. Gibbons R, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am. J. Psychiatry 163(11), 1898-1904 (2006).
94. Juurlink D, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am. J. Psychiatry 163(5), 813-821 (2006).
95. Benvenuti A, Rucci P, Miniati M et al. Treatment-emergent mania/hypomania in unipolar patients. Bipolar Dis. 10(6), 726-732 (2008).
96. Arnold LM, Russell IJ, Diri EW et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fbromyalgia. J. Pain 9(9), 792-805 (2008).
97. Mease PJ, Clauw DJ, Gendreau RM et al. The effcacy and safety of milnacipran for treatment of fbromyalgia. a randomized, double-blind, placebo-controlled trial. J. Rheumatol. 36(2), 398-409 (2009).